Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years.
Paolo Gisondi, Boni Elewski, Andreas Pinter et al.
✦ AI-curated · Sources linked
In 30 seconds
This analysis pooled data from four phase 3/3b randomized trials and an open-label extension to assess bimekizumab for scalp, nail, and palmoplantar psoriasis in adults with moderate to severe plaque psoriasis and involvement of these areas at baseline. Across comparisons with adalimumab, ustekinumab, and secukinumab, complete-clearance rates were generally higher with bimekizumab. After 4 years of bimekizumab treatment, complete clearance was reported in 79.5% for scalp, 61.6% for nails, and 88.7% for palmoplantar psoriasis. The analysis also reported greater patient-reported health-related quality-of-life benefits than with comparators.
Key findings
- At Week 24, scalp/nail/palmoplantar complete-resolution rates were 77.7%/39.8%/78.7% with bimekizumab and 58.1%/24.5%/73.3% with adalimumab.
- At Week 52, rates were 71.9%/54.0%/85.2% with bimekizumab and 51.8%/30.6%/75.0% with ustekinumab.
- At Week 48, rates were 80.6%/69.5%/82.4% with bimekizumab and 71.6%/52.5%/76.8% with secukinumab.
- After 4 years of bimekizumab treatment, complete-clearance rates were 79.5% for scalp, 61.6% for nails, and 88.7% for palmoplantar psoriasis.
Why it matters
Psoriasis affecting the scalp, nails, palms, or soles can interfere with daily activities and quality of life. These trial analyses suggest that bimekizumab can achieve and maintain clearance in these areas, with reported quality-of-life benefits compared with the studied comparators. The findings provide clinically relevant evidence for outcomes in sites that may be particularly burdensome, while reflecting the populations and follow-up represented in the trials.
What to keep in mind
The long-term findings came from an open-label extension, and the analysis combined data from multiple trials with different comparators and assessment time points.